Physician profile
Allen S Anderson
NPI 1083775811
$413,389.51
in general payments reported to CMS, 2019-2025
28 companies · $101K in 2025
The $101K reported for 2025 was more than what 97% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $14K · 2021: $29K · 2022: $69K · 2023: $83K · 2024: $54K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Travel and Lodging: $32K · Consulting Fee: $22K · Food and Beverage: $7,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,154.08 |
| Travel and Lodging | $32,306.41 |
| Consulting Fee | $21,752.50 |
| Food and Beverage | $7,237.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $136,410.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $78,517.99 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64,616.01 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $38,605.03 | 2025 | |
| Bridgebio Pharma, INC. | $23,650.14 | 2025 | Attruby |
| Lilly USA, LLC | $21,214.06 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $14,326.07 | 2019-2022 | |
| Edwards Lifesciences Corporation | $11,937.07 | 2019-2024 | Pascal |
| Ge Healthcare | $10,400.00 | 2019 | |
| Vifor Pharma, INC. | $6,617.95 | 2019 | |
| Pfizer International LLC | $1,800.00 | 2020 | |
| Abiomed | $962.52 | 2021-2023 | Impella |
| Abbott Laboratories | $960.76 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Xience Skypoint |
| Glaxosmithkline, LLC. | $912.08 | 2019 | |
| Cvrx, INC. | $434.01 | 2023-2025 | Barostim Neo System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $417.86 | 2021-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $369.54 | 2024-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $298.32 | 2023-2024 | Optimizer, Optimizer |
| Medtronic Vascular, INC. | $224.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $168.11 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2023 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $116.52 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.63 | 2024 | Lifevest |
| Biotronik INC. | $87.08 | 2019 | |
| Scpharmaceuticals INC. | $38.47 | 2025 | |
| Zoll Circulation INC | $30.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.75 | 2023 | Xarelto |
| Amgen INC. | $20.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.